EcoDrugPlus

Endothelin Receptor Type B

Ensembl ID : ENSSTUG00000014211
Gene Symbol: EDNRB
3 Cross references
192 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSTUG00000010978
Gene Symbol: LOC115202232
3 Cross references
199 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSTUG00000001355
Gene Symbol: LOC115191794
3 Cross references
199 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSTUG00000010807
Gene Symbol: LOC115157349
3 Cross references
190 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSTUG00000006342
Gene Symbol: LOC115169457
3 Cross references
192 Possible Orthologues:

Endothelin-Converting Enzyme 1-Like

Ensembl ID : ENSSTUG00000051083
Gene Symbol: LOC115207711
3 Cross references
224 Possible Orthologues:

Endothelin-Converting Enzyme 1-Like

Ensembl ID : ENSSTUG00000017317
Gene Symbol: LOC115150727
3 Cross references
224 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSSTUG00000044855
Gene Symbol: EZH2
3 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSSTUG00000027691
Gene Symbol: EGFR
3 Cross references
208 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSSTUG00000038507
Gene Symbol: LOC115169555
3 Cross references
206 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSSTUG00000024704
Gene Symbol: LOC115157224
3 Cross references
206 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSSTUG00000009975
Gene Symbol: LOC115193627
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).